MedTrace Logo

Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis

NCT04517734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 338

Last updated 2022-03-22

No results posted yet for this study

Summary

Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.

Conditions

  • Pregnancy Anemia
  • Newborn; Anemia

Sponsors & Collaborators

Principal Investigators

  • Kimberly O'Brien, PhD · Cornell University

  • Elizabeta Nemeth, PhD · University of California, Los Angeles

Eligibility

Min Age
11 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517734 on ClinicalTrials.gov